Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease

Mise à jour : Il y a 4 ans
Référence : NCT02813265

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).


Critère d'inclusion

  • Dry Eye Syndromes,Keratoconjunctivitis Sicca

Liens